# Laboratory Corporation of America Holdings  Share Price Target ‘$240.80’, now 17.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/laboratory-corporation-of-america-holdings-share-price-target-240.80-now-17.9-upside-potential/4121154342
- Published: 2024-05-01T14:05:54+01:00
- Author: Charlotte Edwards

**Laboratory Corporation of America Holdings** which can be found using ticker (
LH) have now 15 analysts in total covering the stock. The consensus rating is pointing
to ‘buy’. The range between the high target price and low target price is between
$262.00 and $210.00 and has a mean share price target at $240.80. (at the time of
writing). Now with the previous closing price of $204.17 and the analysts are correct
then there would likely be a percentage uptick in value of 17.9%. Also worth taking
note is the 50 day moving average now sits at $211.11 and the 200 day moving average
is $212.97. The company has a market cap of 16.98B. The stock price for the company
is currently $201.37 USD

 The potential market cap would be $20,021,052,310 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 43.12, revenue per share of $142.99
and a 3.75% return on assets.

Laboratory Corporation of America Holdings is a global life sciences company. The
Company provides information to help doctors, hospitals, pharmaceutical companies,
researchers, and patients make decisions. The Company’s segments include Labcorp
Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent
clinical laboratory business. It offers a menu of frequently requested and specialty
diagnostic tests through an integrated network of primary and specialty laboratories
across the United States. In addition to diagnostic testing along with occupational
and wellness testing for employers and forensic DNA analysis, Dx segment also offers
a range of other testing services. The DD segment is a contract research organizations
business that provides end-to-end drug development services. The DD segment provides
these services predominantly to pharmaceutical, biotechnology and medical device
companies across the world. It serves clients in more than 100 countries.

Share on: